Cleveland BioLabs, Inc. (CBLI): Price and Financial Metrics

Cleveland BioLabs, Inc. (CBLI)

Today's Latest Price: $2.60 USD

0.04 (-1.52%)

Updated Oct 23 4:00pm

Add CBLI to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 364 in Miscellaneous

See all "A" rated Strong Buy stocks

CBLI Stock Summary

  • Cleveland Biolabs Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.26% of US listed stocks.
  • For CBLI, its debt to operating expenses ratio is greater than that reported by merely 0.36% of US equities we're observing.
  • CBLI's price/sales ratio is 47.95; that's higher than the P/S ratio of 95.73% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Cleveland Biolabs Inc, a group of peers worth examining would be HOLI, CLRO, ISNS, ISSC, and EXFO.
  • Visit CBLI's SEC page to see the company's official filings. To visit the company's web site, go to

CBLI Stock Price Chart Interactive Chart >

Price chart for CBLI

CBLI Price/Volume Stats

Current price $2.60 52-week high $5.43
Prev. close $2.64 52-week low $0.50
Day low $2.50 Volume 476,000
Day high $2.71 Avg. volume 1,613,015
50-day MA $2.15 Dividend yield N/A
200-day MA $2.12 Market Cap 33.84M

CBLI Latest News Stream

Event/Time News Detail
Loading, please wait...

CBLI Latest Social Stream

Loading social stream, please wait...

View Full CBLI Social Stream

Latest CBLI News From Around the Web

Below are the latest news stories about Cleveland Biolabs Inc that investors may wish to consider to help them evaluate CBLI as an investment opportunity.

Cleveland BioLabs joins COVID vaccine-stoked rally

Thinly traded nano cap Cleveland BioLabs ([[CBLI]] +110.5%) is up on a whopping 119x surge in volume, caught up in the COVID-19 tsunami. Investors are falling all over themselves to buy shares in vaccine developers, which are commonly combined with an immune system booster called an adjuvant, in light of...

Seeking Alpha | June 26, 2020

Cleveland BioLabs Closes $3.175 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

BUFFALO, NY / ACCESSWIRE / June 3, 2020 / Cleveland BioLabs, Inc. (CBLI), today announced the closing of its previously announced registered direct offering to several institutional and accredited investors of an aggregate of 1,515,878 shares of its common stock, at a purchase price of $2.0945 per share. The offering was priced at-the-market under Nasdaq rules. Cleveland BioLabs also issued to the investors unregistered warrants to purchase up to an aggregate of 757,939 shares of common stock.

Yahoo | June 3, 2020

Cleveland BioLabs Reports First Quarter 2020 Financial Results and Development Progress

BUFFALO, NY / ACCESSWIRE / May 15, 2020 / Cleveland BioLabs, Inc. (NASDAQ:CBLI) today reported financial results and development progress for the first quarter ended March 31, 2020. Cleveland BioLabs reported ...

Yahoo | May 15, 2020

The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN )(announced early termination of waiting period for its proposed acquisition by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN )) Cidara Therapeutics Inc (NASDAQ: CDTX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )(saw a coronavirus-induced rally ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY )(reacted to its Q3 results) Inovio Pharmaceuticals Inc (NASDAQ: INO )(announced Nevro Corp (NYSE: NVRO ) Oyster Point Pharma Inc (NASDAQ: OYST ) Quest Diagnostics Inc (NYSE: DGX ) Rapt Therapeutics Inc (NASDAQ: RAPT ) SI-Bone Inc (NASDAQ: SIBN ) Va...

Benzinga | January 28, 2020

Coronavirus Link Sends This Nano-Cap Stock Up 150%

Shares of nano-cap Cleveland BioLabs, Inc. (NASDAQ: CBLI ) jumped out of the gate at Monday's open and are sustaining the strong momentum on over 100 times their average volume. The strong move came amid a lack of any significant news from the company. It's apparently in reaction to the coronavirus outbreak in China , which has thus far claimed 80 lives and left about 461 in critical condition. Cleveland BioLabs neither has any coronavirus drug or vaccine in its pipeline nor an experimental one targeting the deadly disease. The company's most … Full story available on

Benzinga Feeds | January 27, 2020

Read More 'CBLI' Stories Here

CBLI Price Returns

1-mo 36.84%
3-mo 0.00%
6-mo 53.85%
1-year 270.26%
3-year -19.25%
5-year -36.27%
YTD 331.89%
2019 -40.40%
2018 -74.81%
2017 182.39%
2016 -59.31%
2015 -37.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7938 seconds.